Table 4 Overview of MVA-H5 panel sera assessed for the presence of VACV-reactive or MPXV-reactive antibodies by ELISA and MVA-neutralizing or MPXV-neutralizing antibodies by PRNT. The timepoints V0 (pre-vaccination), V1 (four weeks after the first vaccination), V2 (four/eight weeks after the first/second vaccination, respectively) and V3 (four weeks after the third vaccination) refer to Fig. 2d
One shot | Two shots | ||||||||
|---|---|---|---|---|---|---|---|---|---|
V0 | V1 | V2 | V3 | V0 | V1 | V2 | V3 | ||
VACV ELISA (107 PFU) | |||||||||
Sera | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | |
Responder | 0 | 1 | 2 | 6 | 0 | 0 | 6 | 6 | |
Percentage (%) | 0 | 17 | 33 | 100 | 0 | 0 | 100 | 100 | |
GMT | 10 | 11 | 12 | 509 | 10 | 10 | 79 | 1,383 | |
MVA PRNT (107 PFU) | |||||||||
Sera | – | – | 6 | 6 | – | – | 6 | 6 | |
Responder | – | – | 0 | 6 | – | – | 2 | 6 | |
Percentage (%) | – | – | 0 | 100 | – | – | 33 | 100 | |
GMT | – | – | 10 | 64 | – | – | 14 | 129 | |
MPXV PRNT (107 PFU) | |||||||||
Sera | – | – | 6 | 6 | – | – | 6 | 6 | |
Responder | – | – | 1 | 6 | – | – | 4 | 6 | |
Percentage (%) | – | – | 17 | 100 | – | – | 67 | 100 | |
GMT | – | – | 10 | 33 | – | – | 16 | 66 | |
VACV ELISA (108 PFU) | |||||||||
Sera | 5 | 5 | 5 | 5 | 3 | 5 | 5 | 5 | |
Responder | 0 | 2 | 2 | 5 | 0 | 2 | 5 | 5 | |
Percentage (%) | 0 | 40 | 40 | 100 | 10 | 40 | 100 | 100 | |
GMT | 10 | 13 | 14 | 1,323 | 10 | 15 | 223 | 2,131 | |
MVA PRNT (108 PFU) | |||||||||
Sera | – | – | 5 | 5 | – | – | 3 | 5 | |
Responder | – | – | 0 | 5 | – | – | 2 | 5 | |
Percentage (%) | – | – | 0 | 100 | – | – | 67 | 100 | |
GMT | – | – | 10 | 131 | – | – | 25 | 301 | |
MPXV PRNT (108 PFU) | |||||||||
Sera | – | – | 5 | 5 | – | – | 3 | 5 | |
Responder | – | – | 1 | 5 | – | – | 1 | 5 | |
Percentage (%) | – | – | 20 | 100 | – | – | 33 | 100 | |
GMT | – | – | 13 | 85 | – | – | 14 | 91 | |
Total | |||||||||
Sex (M/F)a | NA | NA | |||||||
Age (years)a | NA (range, 18–28) | NA (range, 18–28) | |||||||
